BCRPATIENTBARCODE	DRUGCATEGORY	DRUGDOSAGE	DOSAGEUNITS	NUMBERCYCLES	DAYSTODRUGTREATMENTSTART	DAYSTODRUGTREATMENTEND	INITIALCOURSE	DRUGNAME	REGIMENINDICATION	ROUTEOFADMINISTRATION	
TCGA-02-0001	CHEMO	75	mg/m2	4	92	277	null	CRA	ADJUVANT	null	
TCGA-02-0001	CHEMO	null	null	null	null	null	null	CELEBREX	RECURRENCE	ORAL	
TCGA-02-0001	CHEMO	null	null	null	null	null	null	CIS RETINOIC ACID	RECURRENCE	ORAL	
TCGA-02-0001	CHEMO	400	mg	4	92	277	null	CELEBREX	ADJUVANT	null	
TCGA-02-0003	CHEMO	80	mg	1	49	94	null	TAMOXIFEN	ADJUVANT	null	
TCGA-02-0004	CHEMO	200	mg/m2	3	44	153	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0004	CHEMO	75	mg/m2	3	44	153	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0006	CHEMO	null	null	null	null	null	null	TEMOZOLOMIDE	RECURRENCE	ORAL	
TCGA-02-0006	CHEMO	200	mg/m2	7	88	148	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0006	CHEMO	null	null	null	null	null	null	CIS RETINOIC ACID	RECURRENCE	ORAL	
TCGA-02-0007	CHEMO	75	mg/m2/day	5	33	338	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0007	CHEMO	200	mg/m2/day	5	33	338	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0009	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0010	CHEMO	null	null	null	null	null	null	CPT 11	RECURRENCE	null	
TCGA-02-0010	CHEMO	200	mg/m2	2	509	569	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0010	CHEMO	null	null	null	null	null	null	THALIDOMIDE	RECURRENCE	null	
TCGA-02-0011	CHEMO	null	null	null	null	null	null	GEFITINIB	RECURRENCE	null	
TCGA-02-0011	CHEMO	200	mg/m2	4	20	144	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0011	CHEMO	null	null	null	null	null	null	Carboplatin	RECURRENCE	null	
TCGA-02-0011	CHEMO	75	mg/m2	4	20	144	null	TEMOZOLOMIDE	OTHER: SPECIFY IN NOTES	ORAL	
TCGA-02-0014	CHEMO	null	null	null	null	null	null	TEMOZOLOMIDE	RECURRENCE	ORAL	
TCGA-02-0014	CHEMO	null	null	null	2348	null	null	Anti necplatens	ADJUVANT	null	
TCGA-02-0015	CHEMO	1	null	null	0	null	null	BCNU Wafer	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-02-0015	CHEMO	null	null	null	null	null	null	AE 788	RECURRENCE	ORAL	
TCGA-02-0016	CHEMO	200	mg/m2	30	83	1041	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0021	CHEMO	null	null	null	null	null	null	XELODA	RECURRENCE	null	
TCGA-02-0021	CHEMO	200	mg/m2/day	null	72	190	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0021	CHEMO	null	null	null	null	null	null	6 Thiguanine	RECURRENCE	null	
TCGA-02-0021	CHEMO	null	null	null	null	null	null	CELEBREX	RECURRENCE	null	
TCGA-02-0021	CHEMO	null	null	null	null	null	null	LOMUSTINE	RECURRENCE	null	
TCGA-02-0023	CHEMO	null	null	null	null	null	null	TEMOZOLOMIDE	RECURRENCE	ORAL	
TCGA-02-0023	CHEMO	75	mg/m2/day	1	-9	34	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0024	CHEMO	3600	mg/m2	18	151	701	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0025	CHEMO	200	mg/m2/day	18	118	656	null	TEMOZOLOMIDE	ADJUVANT	null	
TCGA-02-0025	CHEMO	null	null	null	null	null	null	Sarasar	RECURRENCE	ORAL	
TCGA-02-0025	CHEMO	null	null	null	null	null	null	TEMOZOLOMIDE	RECURRENCE	ORAL	
TCGA-02-0026	CHEMO	null	null	null	null	null	null	IMATINIB	RECURRENCE	ORAL	
TCGA-02-0026	CHEMO	null	null	null	null	null	null	HYDROXYUREA	RECURRENCE	ORAL	
TCGA-02-0026	CHEMO	150	mg/m2/day	11	92	418	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0027	CHEMO	null	null	null	null	null	null	XELODA	RECURRENCE	null	
TCGA-02-0027	CHEMO	null	null	null	null	null	null	CELEBREX	RECURRENCE	null	
TCGA-02-0027	CHEMO	null	null	null	null	null	null	LOMUSTINE	RECURRENCE	null	
TCGA-02-0027	CHEMO	1200	mg/m2/day	6	27	256	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0027	CHEMO	null	null	null	null	null	null	6 Thiguanine	RECURRENCE	null	
TCGA-02-0028	CHEMO	null	null	null	null	null	null	XELODA	RECURRENCE	ORAL	
TCGA-02-0028	CHEMO	200	mg/m2	12	1939	2304	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0028	CHEMO	null	null	null	null	null	null	TEMOZOLOMIDE	RECURRENCE	ORAL	
TCGA-02-0028	CHEMO	null	null	null	null	null	null	CELEBREX	RECURRENCE	ORAL	
TCGA-02-0033	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0034	CHEMO	200	mg/m2/day	2	89	159	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0037	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0038	CHEMO	150	mg/day	2	112	173	null	Tanceva	ADJUVANT	ORAL	
TCGA-02-0039	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0043	CHEMO	null	null	null	null	null	null	CELEBREX	RECURRENCE	null	
TCGA-02-0043	CHEMO	null	null	null	null	null	null	6 Thiguanine	RECURRENCE	null	
TCGA-02-0043	CHEMO	100	mg/m2	2	297	359	null	LOMUSTINE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0043	CHEMO	null	null	null	null	null	null	LOMUSTINE	RECURRENCE	null	
TCGA-02-0043	CHEMO	null	null	null	null	null	null	XELODA	RECURRENCE	null	
TCGA-02-0046	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0047	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0048	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0051	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0052	CHEMO	200	mg/m2/day	5	34	204	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0054	CHEMO	75	mg/m2/day	1	28	73	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0054	CHEMO	null	null	null	null	null	null	6 Thiguanine	RECURRENCE	null	
TCGA-02-0054	CHEMO	null	null	null	null	null	null	LOMUSTINE	RECURRENCE	null	
TCGA-02-0054	CHEMO	null	null	null	null	null	null	XELODA	RECURRENCE	null	
TCGA-02-0054	CHEMO	null	null	null	null	null	null	CELEBREX	RECURRENCE	null	
TCGA-02-0055	CHEMO	75	mg/m2/day	null	-111	0	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0055	CHEMO	200	mg/m2/day	null	-111	0	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0057	CHEMO	null	null	null	null	null	null	TEMOZOLOMIDE	RECURRENCE	ORAL	
TCGA-02-0057	CHEMO	1	null	null	1	null	null	BCNU Wafer	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-02-0058	CHEMO	75	mg/m2/day	2	20	142	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0059	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0060	CHEMO	600	mg/m2/day	3	15	182	null	TEMOZOLOMIDE	OTHER: SPECIFY IN NOTES	ORAL	
TCGA-02-0060	CHEMO	75	mg/m2	3	15	182	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0064	CHEMO	null	null	null	null	null	null	CPT 11	RECURRENCE	INTRAVENOUS (IV)	
TCGA-02-0064	CHEMO	null	null	null	null	null	null	BEVACIZUMAB	RECURRENCE	INTRAVENOUS (IV)	
TCGA-02-0064	CHEMO	200	mg/m2/day	12	23	358	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0068	CHEMO	null	null	null	null	null	null	BEVACIZUMAB	RECURRENCE	INTRAVENOUS (IV)	
TCGA-02-0068	CHEMO	null	null	null	null	null	null	CPT 11	RECURRENCE	INTRAVENOUS (IV)	
TCGA-02-0068	CHEMO	200	mg/m2	3	14	179	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0068	CHEMO	75	mg/m2/day	3	14	179	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0069	CHEMO	200	mg/m2/day	24	15	945	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0069	CHEMO	75	mg/m2/day	24	15	945	null	TEMOZOLOMIDE	OTHER: SPECIFY IN NOTES	ORAL	
TCGA-02-0070	CHEMO	75	mg/m2/day	1	10	57	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0071	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0074	CHEMO	75	mg/m2/day	3	13	154	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0074	CHEMO	200	mg/m2/day	3	378	154	null	TEMOZOLOMIDE	OTHER: SPECIFY IN NOTES	ORAL	
TCGA-02-0075	CHEMO	75	mg/m2	1	16	36	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0079	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0080	CHEMO	null	null	null	null	null	null	CIS RETINOIC ACID	RECURRENCE	ORAL	
TCGA-02-0080	CHEMO	100	mg/m2/day	4	352	443	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0083	CHEMO	200	mg/m2	11	68	404	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0084	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0085	CHEMO	75	mg/m2/day	1	740	785	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0086	CHEMO	null	null	null	null	null	null	LOMUSTINE	ADJUVANT	null	
TCGA-02-0086	CHEMO	null	null	null	null	null	null	CELEBREX	ADJUVANT	null	
TCGA-02-0086	CHEMO	75	mg/m2	2	13	85	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0086	CHEMO	null	null	null	null	null	null	XELODA	ADJUVANT	null	
TCGA-02-0086	CHEMO	null	null	null	null	null	null	6 Thiguanine	ADJUVANT	null	
TCGA-02-0087	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0089	CHEMO	1400	mg/m2	7	67	282	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0099	CHEMO	null	null	null	null	null	null	TEMOZOLOMIDE	RECURRENCE	ORAL	
TCGA-02-0099	CHEMO	150	mg/m2/day	3	-260	-124	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0102	CHEMO	60	mg/m2/day	5	157	402	null	PROCARBAZINE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0102	CHEMO	1.4	mg/m2/day	5	157	402	null	VINCRISTINEE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0102	CHEMO	110	mg/m2/day	5	157	402	null	LOMUSTINE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0104	CHEMO	75	mg/m2	9	1536	1786	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0104	CHEMO	200	mg/m2/day	9	1536	1786	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0106	CHEMO	500	mg/m2/day	5	15	175	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0106	CHEMO	75	mg/m2/day	5	15	175	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0106	CHEMO	null	null	null	null	null	null	IL 13	RECURRENCE	ORAL	
TCGA-02-0107	CHEMO	200	mg/m2	1	100	130	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0111	CHEMO	75	ug/m2	1	28	74	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0113	CHEMO	4800	mg/m2	24	1929	2627	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0114	CHEMO	110	mg/m2/day	4	75	196	null	LOMUSTINE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0114	CHEMO	60	mg/m2/day	4	75	196	null	PROCARBAZINE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0114	CHEMO	null	null	null	null	null	null	Carboplatin	RECURRENCE	null	
TCGA-02-0114	CHEMO	null	null	null	null	null	null	ERLOTINIB	RECURRENCE	null	
TCGA-02-0114	CHEMO	1.4	mg/m2/day	4	84	196	null	VINCRISTINEE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0115	CHEMO	null	null	null	null	null	null	BEVACIZUMAB	RECURRENCE	INTRAVENOUS (IV)	
TCGA-02-0115	CHEMO	null	null	null	27	107	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0116	CHEMO	900	mg/m2	12	53	388	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-0116	CHEMO	null	null	null	null	null	null	IMATINIB	RECURRENCE	ORAL	
TCGA-02-0116	CHEMO	null	null	null	null	null	null	Hydoxyurea	RECURRENCE	ORAL	
TCGA-02-0258	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0260	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0266	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0269	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0271	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0281	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0285	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0289	CHEMO	110	mg/m2	2	93	181	null	LOMUSTINE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0289	CHEMO	1.4	mg/m2/day	2	93	181	null	VINCRISTINEE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0289	CHEMO	60	mg/m2	2	93	181	null	PROCARBAZINE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0290	CHEMO	110	mg/m2	5	502	3942	null	LOMUSTINE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0290	CHEMO	1.4	mg/m2	5	502	3942	null	VINCRISTINEE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0290	CHEMO	60	mg/m2	5	502	3942	null	PROCARBAZINE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0317	CHEMO	null	null	null	23	176	null	anti neopastons	ADJUVANT	null	
TCGA-02-0321	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0324	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0325	CHEMO	1.4	mg/m2	1	84	115	null	VINCRISTINEE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0325	CHEMO	60	mg/m2	1	84	115	null	PROCARBAZINE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0325	CHEMO	null	null	null	null	null	null	CIS RETINOIC ACID	RECURRENCE	ORAL	
TCGA-02-0325	CHEMO	110	mg/m2	1	84	115	null	LOMUSTINE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0326	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0330	CHEMO	110	mg/m2	1	107	137	null	LOMUSTINE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0330	CHEMO	null	null	null	null	null	null	Carboplatin	RECURRENCE	INTRAVENOUS (IV)	
TCGA-02-0330	CHEMO	60	mg/m2	1	107	137	null	PROCARBAZINE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0330	CHEMO	null	null	null	null	null	null	VP-16	RECURRENCE	INTRAVENOUS (IV)	
TCGA-02-0330	CHEMO	1.4	mg/m2	1	107	137	null	VINCRISTINEE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0332	CHEMO	110	mg/m2	4	98	229	null	LOMUSTINE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0332	CHEMO	1.4	mg/m2	4	98	229	null	VINCRISTINEE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0332	CHEMO	60	mg/m2	4	98	229	null	PROCARBAZINE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0333	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0337	CHEMO	1.4	mg/m2/day	5	185	428	null	VINCRISTINEE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0337	CHEMO	60	mg/m2/day	5	185	428	null	PROCARBAZINE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0337	CHEMO	110	mg/m2/day	5	185	434	null	LOMUSTINE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0338	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0339	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0422	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0430	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0432	CHEMO	100	mg/m2	6	104	329	null	LOMUSTINE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-02-0439	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0440	CHEMO	75	ug/m2	1	269	288	null	CIS RETINOIC ACID	ADJUVANT	ORAL	
TCGA-02-0446	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0451	null	null	null	null	null	null	null	null	null	null	
TCGA-02-0456	null	null	null	null	null	null	null	null	null	null	
TCGA-02-2466	CHEMO	75	mg/m2	null	28	71	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-2466	CHEMO	150	mg/m2	1	72	102	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-2470	CHEMO	75	mg/m2	null	57	98	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-2470	CHEMO	null	mg/m2	3	99	182	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-2483	CHEMO	null	mg/m2	12	94	465	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-2483	CHEMO	75	mg/m2	null	53	93	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-2485	CHEMO	null	mg/m2	4	92	185	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-2485	CHEMO	75	mg/m2	null	51	91	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-2486	CHEMO	null	mg/m2	null	24	66	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-2486	CHEMO	null	mg/m2	12	67	440	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-02-2486	CHEMO	null	mg	4	129	229	null	Accutane	PROGRESSION	ORAL	
TCGA-06-0119	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0121	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0122	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0124	CHEMO	null	null	null	1066	1400	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-0125	CHEMO	200	mg	11	1035	1352	null	THALIDOMIDE	PROGRESSION	ORAL	
TCGA-06-0125	CHEMO	566	mg	2	883	944	null	CPT 11	PROGRESSION	INTRAVENOUS (IV)	
TCGA-06-0125	CHEMO	300	mg	14	28	452	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-0126	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0127	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0128	CHEMO	null	null	13	26	175	null	Suramin	ADJUVANT	ORAL	
TCGA-06-0128	HORMONAL	18	mg	null	600	648	null	TAMOXIFEN	ADJUVANT	null	
TCGA-06-0128	CHEMO	285	mg	2	427	455	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-06-0128	CHEMO	382	mg	1	486	515	null	BCNU	PROGRESSION	INTRAVENOUS (IV)	
TCGA-06-0128	CHEMO	11	mg/m2	6	211	396	null	MGI 114	PROGRESSION	INTRAVENOUS (IV)	
TCGA-06-0129	IMMUNO	19.5	mL	null	182	237	null	IL-13PE	OTHER: SPECIFY IN NOTES	null	
TCGA-06-0129	CHEMO	null	null	2	14	119	null	TEMOZOLOMIDE	OTHER: SPECIFY IN NOTES	ORAL	
TCGA-06-0130	CHEMO	null	null	8	74	280	null	TEMOZOLOMIDE	RECURRENCE	ORAL	
TCGA-06-0133	CHEMO	200	mg	2	14	53	null	EMD 121974	ADJUVANT	INTRAVENOUS (IV)	
TCGA-06-0133	CHEMO	200	mg/m2	2	14	53	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-0133	CHEMO	263	mg	10	79	426	null	CPT 11	PROGRESSION	INTRAVENOUS (IV)	
TCGA-06-0133	CHEMO	927	mg	10	79	426	null	BEVACIZUMAB	PROGRESSION	INTRAVENOUS (IV)	
TCGA-06-0137	CHEMO	null	null	1	636	636	null	BCNU Wafer	RECURRENCE	ORAL	
TCGA-06-0138	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0139	TARGETED	910	mg	null	203	null	null	BEVACIZUMAB	PROGRESSION	null	
TCGA-06-0139	CHEMO	265	mg	3	203	null	null	CPT11	PROGRESSION	INTRAVENOUS (IV)	
TCGA-06-0140	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0141	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0142	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0143	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0145	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0146	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0147	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0148	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0149	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0150	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0151	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0152	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0154	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0155	TARGETED	4	mg/m2	null	9	61	null	CI980	ADJUVANT	null	
TCGA-06-0155	CHEMO	80	mg/m2	2	153	245	null	BCNU	ADJUVANT	INTRAVENOUS (IV)	
TCGA-06-0155	CHEMO	8	{Wafer}	1	257	null	null	BCNU Wafer	PALLIATIVE	OTHER: SPECIFY IN NOTES	
TCGA-06-0156	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0157	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0158	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0159	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0160	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0162	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0164	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0165	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0166	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0167	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0168	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0169	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0171	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0173	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0174	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0175	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0176	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0177	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0178	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0179	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0182	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0184	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0185	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0187	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0188	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0189	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0190	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0192	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0194	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0195	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0197	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0201	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0206	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0208	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0209	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0210	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0211	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0213	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0214	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0216	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0219	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0221	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0237	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0238	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0240	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0241	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0394	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0397	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0402	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0409	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0410	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0412	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0413	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0414	CHEMO	null	null	4	5	370	null	CISPLATIN	ADJUVANT	INTRAVENOUS (IV)	
TCGA-06-0414	CHEMO	null	null	4	5	370	null	BCNU	ADJUVANT	INTRAVENOUS (IV)	
TCGA-06-0644	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0645	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0646	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0648	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0649	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0673	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0675	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0676	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0678	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0680	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0681	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0686	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0743	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0744	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0745	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0747	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0749	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0750	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0875	CHEMO	135	mg	null	null	null	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-0876	CHEMO	350	mg	5	98	271	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-0877	null	null	null	null	null	null	null	null	null	null	
TCGA-06-0878	CHEMO	145	mg	1	-8	53	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-06-0878	CHEMO	242	mg	5	78	null	null	CPT 11	ADJUVANT	INTRAVENOUS (IV)	
TCGA-06-0878	CHEMO	811	mg	5	78	null	null	BEVACIZUMAB	ADJUVANT	INTRAVENOUS (IV)	
TCGA-06-0879	TARGETED	null	null	null	84	null	null	dcVax	ADJUVANT	null	
TCGA-06-0879	CHEMO	200	mg	3	67	null	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-0881	CHEMO	140	mg	2	72	133	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-0881	CHEMO	747.7	mg	2	150	null	null	BEVACIZUMAB	PROGRESSION	INTRAVENOUS (IV)	
TCGA-06-0881	CHEMO	250	mg	2	150	null	null	CPT 11	ADJUVANT	INTRAVENOUS (IV)	
TCGA-06-0882	CHEMO	300	mg	null	160	null	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-1084	CHEMO	500	mg	4	92	212	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-1084	TARGETED	1455	mg	null	242	323	null	BEVACIZUMAB	PROGRESSION	INTRAVENOUS (IV)	
TCGA-06-1086	CHEMO	400	mg	3	61	182	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-1087	CHEMO	75	mg/m2	1	18	75	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-1800	CHEMO	400	mg	6	92	272	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-1801	CHEMO	280	mg	5	92	243	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-1801	CHEMO	227.5	mg	null	243	null	null	CPT 11	PROGRESSION	INTRAVENOUS (IV)	
TCGA-06-1801	CHEMO	815	mg	null	243	null	null	BEVACIZUMAB	PROGRESSION	INTRAVENOUS (IV)	
TCGA-06-1802	CHEMO	845	mg	5	92	null	null	BEVACIZUMAB	ADJUVANT	INTRAVENOUS (IV)	
TCGA-06-1802	CHEMO	680	mg	5	92	null	null	CPT 11	ADJUVANT	INTRAVENOUS (IV)	
TCGA-06-1802	CHEMO	140	mg	1	61	61	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-1805	CHEMO	200	mg/m2	3	30	null	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-2557	null	null	null	null	null	null	null	null	null	null	
TCGA-06-2558	null	null	null	null	null	null	null	null	null	null	
TCGA-06-2559	CHEMO	100	mg	1	27	48	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-2561	CHEMO	618	mg	null	171	null	null	BEVACIZUMAB	PROGRESSION	INTRAVENOUS (IV)	
TCGA-06-2561	CHEMO	201.25	mg	null	171	null	null	CPT 11	PROGRESSION	INTRAVENOUS (IV)	
TCGA-06-2561	CHEMO	125	mg	2	119	148	null	XL 184	PROGRESSION	ORAL	
TCGA-06-2561	CHEMO	120	mg	1	21	63	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-2562	CHEMO	140	mg	1	26	37	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-2563	CHEMO	120	mg	1	27	57	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-2564	CHEMO	null	null	null	null	null	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-2565	CHEMO	75	mg	1	16	63	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-2565	CHEMO	320	mg	2	92	153	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-2565	CHEMO	550	mg	null	193	null	null	BEVACIZUMAB	PROGRESSION	INTRAVENOUS (IV)	
TCGA-06-2565	CHEMO	75	mg	1	123	-211	null	XL 184	ADJUVANT	ORAL	
TCGA-06-2566	CHEMO	null	mg	1	30	69	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-2566	CHEMO	295	mg	1	95	100	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-2567	CHEMO	null	null	1	null	null	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-2569	null	null	null	null	null	null	null	null	null	null	
TCGA-06-2570	CHEMO	130	mg	1	19	61	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-06-2570	CHEMO	350	mg	8	92	null	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0244	TARGETED	500	mg/day	null	34	484	null	THALIDOMIDE	ADJUVANT	null	
TCGA-08-0244	CHEMO	null	null	null	34	74	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0245	CHEMO	150	mg/m2	3	933	1065	null	BCNU	PROGRESSION	INTRAVENOUS (IV)	
TCGA-08-0245	CHEMO	150	mg/m2	12	560	843	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-08-0245	CHEMO	150	mg/m2	1	875	933	null	BCNU	PROGRESSION	ORAL	
TCGA-08-0245	HORMONAL	200	mg	null	878	933	null	null	PROGRESSION	null	
TCGA-08-0246	CHEMO	null	null	null	35	92	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0344	CHEMO	null	null	7	2586	2850	null	BCNU	PROGRESSION	ORAL	
TCGA-08-0345	null	null	null	null	null	null	null	null	null	null	
TCGA-08-0346	CHEMO	300	mg	1	20	68	null	HYDROXYUREA	ADJUVANT	ORAL	
TCGA-08-0347	CHEMO	350	mg	4	486	605	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-08-0347	CHEMO	300	mg/m2	1	10	54	null	HYDROXYUREA	ADJUVANT	ORAL	
TCGA-08-0347	CHEMO	400	mg	6	69	419	null	BCNU	PROGRESSION	INTRAVENOUS (IV)	
TCGA-08-0347	CHEMO	100	mg/m2	1	422	465	null	PROCARBAZINE	PROGRESSION	ORAL	
TCGA-08-0348	CHEMO	null	null	null	-59	287	null	VP-16	PROGRESSION	INTRAVENOUS (IV)	
TCGA-08-0348	CHEMO	null	null	null	27	203	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0348	TARGETED	1000	mg/day	null	27	135	null	THALIDOMIDE	ADJUVANT	null	
TCGA-08-0348	TARGETED	180	mg/day	null	214	287	null	TAMOXIFEN	PROGRESSION	null	
TCGA-08-0349	CHEMO	150	mg/m2/day	1	37	92	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0349	CHEMO	480	mg	2	104	182	null	BCNU	PROGRESSION	ORAL	
TCGA-08-0349	TARGETED	200	mg/day	null	37	92	null	THALIDOMIDE	ADJUVANT	null	
TCGA-08-0349	CHEMO	2600	mg/day	1	231	259	null	Fenretinide	PROGRESSION	ORAL	
TCGA-08-0350	CHEMO	null	null	5	455	637	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-08-0350	TARGETED	450	mg/day	null	678	837	null	ERLOTINIB	PROGRESSION	null	
TCGA-08-0351	CHEMO	null	null	null	1580	null	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-08-0351	CHEMO	null	null	null	59	null	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0351	TARGETED	200	mg	null	1580	null	null	THALIDOMIDE	PROGRESSION	null	
TCGA-08-0351	TARGETED	null	mg/day	null	59	580	null	THALIDOMIDE	ADJUVANT	null	
TCGA-08-0352	null	null	null	null	null	null	null	null	null	null	
TCGA-08-0353	CHEMO	null	null	1	6	76	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0353	CHEMO	200	mg/m2/day	2	121	174	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0354	CHEMO	380	mg	2	345	390	null	BCNU	PROGRESSION	INTRAVENOUS (IV)	
TCGA-08-0354	CHEMO	.8	mL	8	28	253	null	Poly LCLC	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-08-0354	CHEMO	180	mg	1	345	393	null	CIS RETINOIC ACID	PROGRESSION	INTRAVENOUS (IV)	
TCGA-08-0354	TARGETED	450	mg/day	null	261	320	null	ERLOTINIB	PROGRESSION	null	
TCGA-08-0354	CHEMO	200	mg/day	2	261	320	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-08-0355	CHEMO	75	mg/m2	1	25	68	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0355	TARGETED	1000	mg/day	null	531	572	null	Thalomid	PROGRESSION	null	
TCGA-08-0355	CHEMO	210	mg	1	531	531	null	BCNU	PROGRESSION	INTRAVENOUS (IV)	
TCGA-08-0355	CHEMO	590	mg	1	582	582	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-08-0355	TARGETED	540	mg	null	573	607	null	TAMOXIFEN	PROGRESSION	null	
TCGA-08-0355	TARGETED	null	null	null	640	671	null	Enzastaurin	PROGRESSION	null	
TCGA-08-0355	CHEMO	150	mg/m2	14	88	498	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0356	CHEMO	200	mg	12	92	447	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0356	CHEMO	75	mg/day	1	42	82	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0357	CHEMO	1000	mg/day	1	689	733	null	Hyrdroxyurea	PROGRESSION	ORAL	
TCGA-08-0357	TARGETED	null	null	null	93	136	null	THALIDOMIDE	ADJUVANT	null	
TCGA-08-0357	CHEMO	75	mg	1	29	71	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0357	IMMUNO	36	mg	null	184	188	null	IL-13 Pseudomonas exotoxin	PROGRESSION	null	
TCGA-08-0357	TARGETED	5	mg/day	null	736	860	null	RAPAMYCIN	PROGRESSION	null	
TCGA-08-0357	CHEMO	75	mg	1	93	136	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0357	TARGETED	775	mg	null	471	688	null	CPT 11	PROGRESSION	null	
TCGA-08-0357	TARGETED	400	mg/day	null	1007	1084	null	Sorafenib	PROGRESSION	null	
TCGA-08-0357	TARGETED	475	mg	null	471	688	null	BEVACIZUMAB	PROGRESSION	null	
TCGA-08-0357	TARGETED	1000	mg/day	null	689	733	null	IMATINIB	PROGRESSION	null	
TCGA-08-0357	CHEMO	110	mg/m2	3	736	860	null	LOMUSTINE	PROGRESSION	ORAL	
TCGA-08-0357	TARGETED	100	mg	null	1007	1084	null	Tarveca	PROGRESSION	null	
TCGA-08-0357	CHEMO	100	mg	3	875	985	null	VP-16	PROGRESSION	ORAL	
TCGA-08-0357	IMMUNO	null	null	null	736	860	null	Interferon Alpha	PROGRESSION	null	
TCGA-08-0357	TARGETED	100	mg/day	null	1097	1112	null	Cytoxan	PROGRESSION	null	
TCGA-08-0358	CHEMO	200	mg/m2	6	90	263	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0358	TARGETED	200	mg/day	null	90	263	null	ERLOTINIB	ADJUVANT	null	
TCGA-08-0358	CHEMO	150	mg/day	1	33	75	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0358	IMMUNO	0.4	mg	null	341	466	null	HSPPC-96 Vaccine	PROGRESSION	null	
TCGA-08-0358	TARGETED	150	mg/day	null	33	75	null	ERLOTINIB	ADJUVANT	null	
TCGA-08-0358	CHEMO	220	mg	1	490	547	null	LOMUSTINE	PROGRESSION	ORAL	
TCGA-08-0358	IMMUNO	36	mg	null	287	292	null	IL-13 with Pseudomonas Exotoxin	PROGRESSION	null	
TCGA-08-0359	null	null	null	null	null	null	null	null	null	null	
TCGA-08-0360	IMMUNO	36	mg	null	130	134	null	IL-13 with Pseudomonas exotoxin	PROGRESSION	null	
TCGA-08-0373	null	null	null	null	null	null	null	null	null	null	
TCGA-08-0375	null	null	null	null	null	null	null	null	null	null	
TCGA-08-0380	CHEMO	50	mg/m2	1	293	330	null	VP-16	PROGRESSION	ORAL	
TCGA-08-0380	CHEMO	345	mg	null	581	274	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-08-0380	TARGETED	null	null	null	275	330	null	null	PROGRESSION	null	
TCGA-08-0380	TARGETED	200	mg/day	null	467	516	null	Marimastat	ADJUVANT	null	
TCGA-08-0380	CHEMO	375	mg	1	161	193	null	BCNU	PROGRESSION	INTRAVENOUS (IV)	
TCGA-08-0385	null	null	null	null	null	null	null	null	null	null	
TCGA-08-0386	TARGETED	200	mg/day	null	94	106	null	ERLOTINIB	ADJUVANT	null	
TCGA-08-0386	CHEMO	null	null	11	95	427	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0386	IMMUNO	0.4	mg	null	113	125	null	HSPPC-96 Vaccine	PROGRESSION	null	
TCGA-08-0386	TARGETED	200	mg/day	null	29	76	null	ERLOTINIB	ADJUVANT	null	
TCGA-08-0386	CHEMO	75	mg/m2/day	1	29	76	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0389	TARGETED	null	null	null	30	null	null	EMD	ADJUVANT	null	
TCGA-08-0389	CHEMO	null	null	null	-1826	null	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0390	CHEMO	150	mg/day	1	28	69	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0390	CHEMO	300	mg	1	105	132	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0390	IMMUNO	150	mg	null	105	132	null	ERLOTINIB	ADJUVANT	ORAL	
TCGA-08-0390	IMMUNO	100	mg	null	28	69	null	ERLOTINIB	ADJUVANT	ORAL	
TCGA-08-0392	null	null	null	null	null	null	null	null	null	null	
TCGA-08-0509	null	null	null	null	null	null	null	null	null	null	
TCGA-08-0510	TARGETED	null	mg	null	40	63	null	THALIDOMIDE	ADJUVANT	null	
TCGA-08-0510	CHEMO	330	mg/day	2	34	89	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0511	CHEMO	210	mg	null	null	null	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-08-0512	null	null	null	null	null	null	null	null	null	null	
TCGA-08-0514	null	null	null	null	null	null	null	null	null	null	
TCGA-08-0516	null	null	null	null	null	null	null	null	null	null	
TCGA-08-0517	CHEMO	160	mg/day	null	null	1754	null	Accutane	PROGRESSION	ORAL	
TCGA-08-0517	CHEMO	null	null	6	1095	1359	null	PROCARBAZINE/LOMUSTINE/VINCRISTINEE	PROGRESSION	ORAL	
TCGA-08-0518	null	null	null	null	null	null	null	null	null	null	
TCGA-08-0520	CHEMO	200	mg/m2	null	180	null	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-08-0521	CHEMO	140	mg	1	27	63	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0521	CHEMO	300	mg	1	99	126	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0522	IMMUNO	1	mg	null	268	271	null	IL-13-PE38QQR Cytoxin	PROGRESSION	null	
TCGA-08-0522	CHEMO	140	mg	1	22	65	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0522	TARGETED	null	null	null	423	511	null	LY317615	PROGRESSION	null	
TCGA-08-0522	CHEMO	280	mg	4	61	214	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0522	CHEMO	null	null	1	517	555	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-08-0524	CHEMO	120	mg/day	1	24	52	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0524	CHEMO	170	mg	1	194	198	null	LOMUSTINE	PROGRESSION	ORAL	
TCGA-08-0524	TARGETED	null	null	null	194	296	null	THALIDOMIDE	PROGRESSION	null	
TCGA-08-0524	TARGETED	150	mg	null	73	122	null	SCH63666	PROGRESSION	null	
TCGA-08-0524	TARGETED	350	mg	null	137	188	null	IMATINIB	PROGRESSION	null	
TCGA-08-0525	TARGETED	null	null	null	370	402	null	OS1-774	PROGRESSION	null	
TCGA-08-0525	CHEMO	75	mg/m2/day	1	6	39	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0525	CHEMO	null	null	null	37	341	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0529	CHEMO	200	mg	7	106	328	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0529	CHEMO	75	mg/day	1	41	84	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0529	IMMUNO	36	mg	null	349	353	null	IL-13 Pseudomonas exotoxin	PROGRESSION	null	
TCGA-08-0531	CHEMO	135	mg	1	27	69	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0531	CHEMO	300	mg	4	102	198	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-08-0623	null	null	null	null	null	null	null	null	null	null	
TCGA-08-0625	null	null	null	null	null	null	null	null	null	null	
TCGA-08-0626	null	null	null	null	null	null	null	null	null	null	
TCGA-08-0627	null	null	null	null	null	null	null	null	null	null	
TCGA-12-0615	TARGETED	10	mg/kg	null	277	383	null	BEVACIZUMAB	PROGRESSION	null	
TCGA-12-0615	CHEMO	150	mg/m2	2	101	171	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0615	TARGETED	10	mg	null	194	277	null	BEVACIZUMAB	PROGRESSION	null	
TCGA-12-0615	CHEMO	75	mg/m2	1	null	null	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0615	CHEMO	8	{Wafer}	1	28	28	null	BCNU wafers	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-12-0615	CHEMO	125	mg/m2	2	194	277	null	CPT-11	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0616	TARGETED	10	mg/kg	null	260	348	null	BEVACIZUMAB	ADJUVANT	null	
TCGA-12-0616	TARGETED	2.5	mg	null	406	432	null	Rad001	PROGRESSION	null	
TCGA-12-0616	CHEMO	75	mg/m2	1	29	74	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0616	CHEMO	200	mg/m2	4	105	259	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0616	CHEMO	200	mg/m2	2	362	406	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0616	CHEMO	340	mg/m2	2	260	348	null	CPT-11	ADJUVANT	INTRAVENOUS (IV)	
TCGA-12-0616	TARGETED	700	mg	null	406	432	null	IMATINIB	PROGRESSION	null	
TCGA-12-0616	CHEMO	1000	mg	2	406	432	null	HYDROXYUREA	PROGRESSION	ORAL	
TCGA-12-0618	CHEMO	8	{Wafer}	1	0	0	null	BCNU wafers	ADJUVANT	INTRATUMORAL	
TCGA-12-0618	CHEMO	150	mg/m2	2	8	64	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0619	CHEMO	200	mg/m2	2	228	291	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-0619	CHEMO	50	mg/m2	4	443	571	null	VP-16	PROGRESSION	ORAL	
TCGA-12-0619	CHEMO	8	{Wafer}	1	0	0	null	BCNU Wafers	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-12-0619	CHEMO	110	mg/m2	1	84	129	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0619	CHEMO	150	mg/m2	2	21	84	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0619	CHEMO	82.5	mg/m2	1	163	203	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0619	CHEMO	50	mg/m2	2	291	350	null	VP-16	PROGRESSION	ORAL	
TCGA-12-0620	CHEMO	75	mg/m2	1	21	68	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0620	CHEMO	110	mg/m2	2	92	191	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0654	TARGETED	120	mCi	null	44	216	null	MAb I-131	ADJUVANT	null	
TCGA-12-0654	TARGETED	20	mg	null	44	216	null	mu81c6	ADJUVANT	null	
TCGA-12-0656	CHEMO	50	mg/m2	1	1873	1899	null	VP-16	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0656	CHEMO	55	mg/m2	1	203	253	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0656	CHEMO	82.5	mg/m2	1	1817	1873	null	LOMUSTINE	PROGRESSION	ORAL	
TCGA-12-0656	CHEMO	37.5	mg/m2	2	301	443	null	VP-16	ADJUVANT	INTRAVENOUS (IV)	
TCGA-12-0656	TARGETED	120	mCi	null	22	22	null	MAb I-131	ADJUVANT	null	
TCGA-12-0656	CHEMO	200	mg/m2	6	1488	1758	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-0656	CHEMO	110	mg/m2	1	1758	1817	null	LOMUSTINE	PROGRESSION	ORAL	
TCGA-12-0656	CHEMO	110	mg/m2	1	134	203	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0656	TARGETED	20	mg	null	22	22	null	mu81c6	ADJUVANT	null	
TCGA-12-0657	null	null	null	null	null	null	null	null	null	null	
TCGA-12-0662	CHEMO	200	mg/m2	7	626	843	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-0662	CHEMO	75	mg/m2	3	888	1028	null	CPT-11	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0662	CHEMO	100	mg/m2	2	417	472	null	VP-16	ADJUVANT	ORAL	
TCGA-12-0662	CHEMO	50	mg/m2	1	1041	1070	null	VP-16	PROGRESSION	ORAL	
TCGA-12-0662	CHEMO	100	mg	1	1041	1070	null	Cytoxan	PROGRESSION	ORAL	
TCGA-12-0662	CHEMO	8	{Wafer}	1	875	875	null	BCNU Wafers	PROGRESSION	INTRATUMORAL	
TCGA-12-0662	IMMUNO	400	mg	null	1073	1090	null	THALIDOMIDE	PROGRESSION	null	
TCGA-12-0662	TARGETED	120	mg/m2	null	1133	1135	null	06GB	PROGRESSION	null	
TCGA-12-0662	CHEMO	100	mg/m2	2	223	278	null	VP-16	ADJUVANT	ORAL	
TCGA-12-0662	CHEMO	110	mg/m2	2	340	417	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0662	CHEMO	150	mg/m2	1	599	603	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-0662	CHEMO	110	mg/m2	2	119	220	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0662	HORMONAL	100	mg	null	278	334	null	Tamoxiten	ADJUVANT	null	
TCGA-12-0662	TARGETED	30	mg/m2	null	1133	1135	null	06GB	PROGRESSION	null	
TCGA-12-0662	CHEMO	10	mg/m2	null	1133	1137	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-0662	HORMONAL	200	mg	null	472	599	null	TAMOXIFEN	ADJUVANT	null	
TCGA-12-0662	IMMUNO	400	mg	null	1113	1161	null	Celbrex	PROGRESSION	ORAL	
TCGA-12-0670	IMMUNO	125	mg/m2	null	327	378	null	CELEBREX	ADJUVANT	ORAL	
TCGA-12-0670	HORMONAL	200	mg	null	601	722	null	TAMOXIFEN	ADJUVANT	ORAL	
TCGA-12-0670	IMMUNO	125	mg/m2	null	448	516	null	CELEBREX	ADJUVANT	ORAL	
TCGA-12-0670	IMMUNO	125	mg/m2	null	722	770	null	CELEBREX	ADJUVANT	ORAL	
TCGA-12-0670	CHEMO	110	mg/m2	2	516	576	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0670	CHEMO	110	mg/m2	2	211	288	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0670	IMMUNO	125	mg/m2	null	601	722	null	CELEBREX	ADJUVANT	ORAL	
TCGA-12-0670	CHEMO	125	mg/m2	1	329	378	null	CPT-11	ADJUVANT	INTRAVENOUS (IV)	
TCGA-12-0670	CHEMO	200	mg/m2	2	448	516	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0670	CHEMO	110	mg/m2	1	578	601	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0670	HORMONAL	200	mg	null	578	601	null	TAMOXIFEN	ADJUVANT	ORAL	
TCGA-12-0670	TARGETED	10	mg	null	43	77	null	ch81c6	ADJUVANT	null	
TCGA-12-0670	HORMONAL	200	mg	null	516	576	null	TAMOXIFEN	ADJUVANT	ORAL	
TCGA-12-0670	CHEMO	150	mg/m2	1	148	183	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0670	CHEMO	200	mg/m2	1	183	203	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0670	HORMONAL	200	mg	null	448	516	null	TAMOXIFEN	ADJUVANT	ORAL	
TCGA-12-0670	IMMUNO	125	mg/m2	null	407	448	null	CELEBREX	ADJUVANT	ORAL	
TCGA-12-0670	IMMUNO	125	mg/m2	null	578	601	null	CELEBREX	ADJUVANT	ORAL	
TCGA-12-0670	TARGETED	80	mCi	null	43	77	null	MAB I131	ADJUVANT	null	
TCGA-12-0670	CHEMO	125	mg/m2	1	407	448	null	CPT-11	ADJUVANT	INTRAVENOUS (IV)	
TCGA-12-0670	IMMUNO	125	mg/m2	null	516	576	null	CELEBREX	ADJUVANT	ORAL	
TCGA-12-0688	CHEMO	340	mg/m2	1	605	649	null	CPT-11	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0688	CHEMO	25	mg	3	649	734	null	VP-16	PROGRESSION	ORAL	
TCGA-12-0688	HORMONAL	100	mg	null	238	353	null	Tamoxiten	ADJUVANT	null	
TCGA-12-0688	CHEMO	110	mg/m2	2	96	179	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0688	CHEMO	25	mg/m2	3	238	353	null	VP-16	ADJUVANT	ORAL	
TCGA-12-0688	CHEMO	150	mg/m2	3	501	597	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0688	CHEMO	37.5	mg/m2	1	215	238	null	VP-16	ADJUVANT	ORAL	
TCGA-12-0691	CHEMO	150	mg/m2	1	116	158	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-0691	CHEMO	200	mg/m2	1	158	185	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-0692	CHEMO	200	mg/m2	1	14	45	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0703	TARGETED	20	mg	null	13	-240	null	mu81c6	ADJUVANT	null	
TCGA-12-0703	CHEMO	0.75	mg/m2	5	321	529	null	Topecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0703	CHEMO	125	mg/m2	3	214	301	null	CPT-11	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0703	TARGETED	120	mCi	null	13	125	null	MAb I-131	ADJUVANT	INTRAVENOUS (IV)	
TCGA-12-0703	CHEMO	100	mg	5	321	529	null	BCNU	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0707	null	null	null	null	null	null	null	null	null	null	
TCGA-12-0769	CHEMO	200	mg/m2	2	192	250	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0769	CHEMO	null	null	2	250	341	null	cpt-11	ADJUVANT	INTRAVENOUS (IV)	
TCGA-12-0769	CHEMO	110	mg/m2	2	91	192	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0769	CHEMO	200	mg/m2	2	33	78	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0772	CHEMO	100	mg	5	1307	1468	null	Cytoxan	PROGRESSION	ORAL	
TCGA-12-0772	TARGETED	10	mg	null	1468	1526	null	BEVACIZUMAB	PROGRESSION	null	
TCGA-12-0772	TARGETED	10	mg/kg	null	1529	1616	null	BEVACIZUMAB	PROGRESSION	null	
TCGA-12-0772	TARGETED	10	mg	null	1468	1526	null	RAPAMYCIN	PROGRESSION	null	
TCGA-12-0772	CHEMO	50	mg/m2	3	1529	1616	null	VP-16	PROGRESSION	ORAL	
TCGA-12-0772	CHEMO	125	mg/m2	6	670	951	null	CPT-11	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0772	TARGETED	150	mg/kg	null	1468	1526	null	ERLOTINIB	PROGRESSION	null	
TCGA-12-0772	CHEMO	50	mg/m2	12	120	489	null	VP-16	ADJUVANT	ORAL	
TCGA-12-0772	CHEMO	82.5	mg/m2	1	1224	1265	null	LOMUSTINE	PROGRESSION	ORAL	
TCGA-12-0772	CHEMO	110	mg/m2	3	951	1112	null	LOMUSTINE	PROGRESSION	ORAL	
TCGA-12-0772	CHEMO	150	mg/m2	2	79	120	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0772	TARGETED	12.5	mg	null	621	670	null	ARIAD AP23573	PROGRESSION	null	
TCGA-12-0772	CHEMO	50	mg/m2	2	1112	1174	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-0772	TARGETED	10	mg/kg	null	1307	1468	null	BEVACIZUMAB	PROGRESSION	null	
TCGA-12-0773	CHEMO	150	mg/m2	2	431	516	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0773	CHEMO	150	mg/m2	2	150	245	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0773	CHEMO	150	mg/m2	2	773	510	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-0773	CHEMO	82.5	mg/m2	2	892	1015	null	LOMUSTINE	PROGRESSION	ORAL	
TCGA-12-0773	TARGETED	10	mg	null	55	56	null	MU81C6	ADJUVANT	null	
TCGA-12-0773	CHEMO	82.5	mg/m2	2	516	607	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0773	HORMONAL	100	mg	null	607	725	null	TAMOXIFEN	ADJUVANT	null	
TCGA-12-0773	CHEMO	50	mg/m2	2	1141	1274	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-0773	TARGETED	10	mg/kg	null	1141	1274	null	BEVACIZUMAB	PROGRESSION	null	
TCGA-12-0773	CHEMO	82.5	mg/m2	2	235	326	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0773	CHEMO	125	mg/m2	2	326	431	null	CPT-11	ADJUVANT	INTRAVENOUS (IV)	
TCGA-12-0773	CHEMO	50	mg/m2	2	1062	1141	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-0773	TARGETED	61	mCi	null	55	56	null	MAb I-131	ADJUVANT	null	
TCGA-12-0773	TARGETED	10	mg	null	55	56	null	mu81c6	ADJUVANT	null	
TCGA-12-0773	CHEMO	37.5	mg/m2	1	1015	1036	null	VP-16	PROGRESSION	ORAL	
TCGA-12-0773	CHEMO	50	mg/m2	2	1274	1311	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-0775	CHEMO	160	mg/m2	2	37	94	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0775	CHEMO	90	mg/m2	1	117	158	null	LOMUSTINE	PROGRESSION	ORAL	
TCGA-12-0776	CHEMO	340	mg/m2	2	140	275	null	CPT-11	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0776	CHEMO	75	mg/m2	1	33	74	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0776	CHEMO	110	mg/m2	1	82	127	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0776	TARGETED	10	mg/kg	null	140	275	null	BEVACIZUMAB	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0778	TARGETED	200	mg	null	355	385	null	ERLOTINIB	PROGRESSION	ORAL	
TCGA-12-0778	CHEMO	110	mg	2	146	231	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0778	TARGETED	10	mg/kg	null	249	329	null	BEVACIZUMAB	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0778	CHEMO	200	mg/m2	2	88	146	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0778	TARGETED	15	mg/day	null	355	385	null	RAPAMYCIN	PROGRESSION	ORAL	
TCGA-12-0778	TARGETED	150	mg	null	355	385	null	Rapamcyin	PROGRESSION	ORAL	
TCGA-12-0778	CHEMO	50	mg/m2	1	329	352	null	VP-16	PROGRESSION	ORAL	
TCGA-12-0778	CHEMO	75	mg/m2	1	22	67	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0778	CHEMO	50	mg/m2	3	249	329	null	VP-16	PROGRESSION	ORAL	
TCGA-12-0778	CHEMO	50	mg/m2	1	329	352	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-0780	CHEMO	125	mg/m2	6	101	350	null	CPT-11	ADJUVANT	INTRAVENOUS (IV)	
TCGA-12-0780	TARGETED	150	mg	null	393	434	null	RAPAMYCIN	PROGRESSION	null	
TCGA-12-0780	CHEMO	37.5	mg/m2	1	360	388	null	VP-16	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0780	CHEMO	75	mg/m2	1	21	77	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-0780	TARGETED	10	mg/kg	null	360	388	null	BEVACIZUMAB	PROGRESSION	null	
TCGA-12-0780	TARGETED	5	mg	null	393	434	null	ERLOTINIB	PROGRESSION	null	
TCGA-12-0780	TARGETED	10	mg/kg	null	111	350	null	BEVACIZUMAB	ADJUVANT	null	
TCGA-12-0818	CHEMO	110	mg/m2	1	135	1642	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0818	CHEMO	50	mg/m2	1	212	254	null	VP-16	ADJUVANT	ORAL	
TCGA-12-0818	CHEMO	110	mg/m2	1	254	295	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0818	CHEMO	50	mg/m2	2	75	135	null	VP-16	ADJUVANT	ORAL	
TCGA-12-0818	TARGETED	80	mCi	null	26	47	null	MAB I-131	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-12-0818	TARGETED	10	mg	null	26	47	null	81c6	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-12-0819	CHEMO	600	mg	4	989	1102	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0819	TARGETED	9.9	mg	null	5	179	null	mu81c6	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-12-0819	CHEMO	150	mg/m2	4	504	624	null	PROCARBAZINE	PROGRESSION	ORAL	
TCGA-12-0819	CHEMO	150	mg/m2	1	375	441	null	BCNU	ADJUVANT	ORAL	
TCGA-12-0819	CHEMO	2.6	mg/m2	1	441	494	null	Topotecan	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0819	CHEMO	200	mg/m2	2	258	375	null	BCNU	ADJUVANT	ORAL	
TCGA-12-0819	TARGETED	60	mCi	null	5	179	null	MAB I 131	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-12-0820	CHEMO	400	mg/m2	1	433	502	null	CPT-11	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0820	HORMONAL	200	mg	null	502	543	null	TAMOXIFEN	PROGRESSION	ORAL	
TCGA-12-0820	CHEMO	62.5	mg/m2	1	502	543	null	VP-16	PROGRESSION	ORAL	
TCGA-12-0820	CHEMO	150	mg/m2	2	216	272	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0820	TARGETED	100	mg/m2	null	-1	0	null	06-BG	ADJUVANT	INTRAVENOUS (IV)	
TCGA-12-0820	TARGETED	100	mg/m2	null	300	341	null	06-BG	PROGRESSION	null	
TCGA-12-0820	CHEMO	300	mg/m2	1	342	363	null	CPT-11	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0820	CHEMO	13.5	mg/m2	1	300	341	null	BCNU	PROGRESSION	ORAL	
TCGA-12-0820	CHEMO	350	mg/m2	1	363	433	null	CPT-11	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0821	CHEMO	190	mg/m2	1	271	296	null	CPT-11	PROGRESSION	ORAL	
TCGA-12-0821	CHEMO	50	mg/m2	2	203	259	null	VP-16	PROGRESSION	ORAL	
TCGA-12-0821	CHEMO	110	mg/m2	2	123	165	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0822	CHEMO	50	mg/m2	1	587	623	null	VP-16	PROGRESSION	ORAL	
TCGA-12-0822	TARGETED	300	mg	null	624	651	null	SCH6636	PROGRESSION	ORAL	
TCGA-12-0822	CHEMO	100	mg/m2	2	189	280	null	BCNU	PROGRESSION	ORAL	
TCGA-12-0822	CHEMO	200	mg/m2	10	280	582	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-0822	TARGETED	150	mg	null	624	624	null	SCH66336	PROGRESSION	ORAL	
TCGA-12-0822	CHEMO	40	mg/m2	1	125	174	null	BCNU	ADJUVANT	ORAL	
TCGA-12-0822	TARGETED	40	mg/m2	null	189	280	null	O6BG	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0822	CHEMO	150	mg/m2	1	125	174	null	CPT-11	ADJUVANT	ORAL	
TCGA-12-0826	null	null	null	null	null	null	null	null	null	null	
TCGA-12-0827	CHEMO	200	mg/m2	1	350	390	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0827	CHEMO	410	mg/m2	1	390	434	null	CPT-11	ADJUVANT	INTRAVENOUS (IV)	
TCGA-12-0827	CHEMO	200	mg/m2	4	466	615	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0827	HORMONAL	160	mg	null	615	746	null	TAMOXIFEN	ADJUVANT	ORAL	
TCGA-12-0827	TARGETED	120	mCi	null	34	76	null	MABI131	ADJUVANT	null	
TCGA-12-0827	CHEMO	82.5	mg/m2	1	181	258	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0827	CHEMO	150	mg/m2	1	258	350	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0827	CHEMO	110	mg/m2	1	137	181	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-0827	TARGETED	20	mg	null	34	76	null	81C6	ADJUVANT	null	
TCGA-12-0828	CHEMO	200	mg/m2	4	28	151	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0829	CHEMO	50	mg/m2	4	474	571	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-0829	TARGETED	10	mg/kg	null	572	599	null	BEVACIZUMAB	PROGRESSION	null	
TCGA-12-0829	CHEMO	200	mg/m2	6	95	473	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0829	CHEMO	75	mg/m2	1	16	64	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-0829	CHEMO	125	mg/m2	1	572	599	null	CPT-11	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0829	TARGETED	10	mg/kg	null	474	571	null	BEVACIZUMAB	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-0829	IMMUNO	1	mL	null	115	473	null	ATTAC	ADJUVANT	null	
TCGA-12-1088	CHEMO	82.5	mg/m2	1	3779	3820	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-1088	CHEMO	110	mg/m2	1	3735	3779	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-1089	CHEMO	110	mg/m2	1	105	147	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-12-1090	CHEMO	100	mg	2	125	190	null	Cyclophosphamide	PROGRESSION	ORAL	
TCGA-12-1090	CHEMO	800	mg	2	125	190	null	THALIDOMIDE	PROGRESSION	ORAL	
TCGA-12-1090	CHEMO	8	{Wafer}	1	45	45	null	BCNU Waters	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-12-1091	CHEMO	80	mg/m2	1	288	330	null	CCNG	PROGRESSION	ORAL	
TCGA-12-1091	CHEMO	150	mg/m2	1	453	484	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-1091	CHEMO	300	mg/m2	3	521	691	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-1091	CHEMO	100	mg/m2	2	819	926	null	VP-16	PROGRESSION	ORAL	
TCGA-12-1091	CHEMO	150	mg/m2	1	179	206	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-1091	HORMONAL	160	mg	null	484	521	null	TAMOXIFEN	PROGRESSION	ORAL	
TCGA-12-1091	CHEMO	90	mg/m2	1	229	287	null	CCNG	PROGRESSION	ORAL	
TCGA-12-1091	CHEMO	125	mg/m2	1	484	521	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-1091	CHEMO	200	mg/m2	1	143	169	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-1091	HORMONAL	160	mg	null	358	453	null	TAMOXIFEN	PROGRESSION	ORAL	
TCGA-12-1091	HORMONAL	120	mg	null	521	691	null	Tamoxiten	PROGRESSION	ORAL	
TCGA-12-1091	CHEMO	200	mg/m2	1	331	358	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-1091	CHEMO	100	mg/m2	2	358	453	null	VP-16	PROGRESSION	ORAL	
TCGA-12-1091	HORMONAL	160	mg	null	453	484	null	TAMOXIFEN	PROGRESSION	ORAL	
TCGA-12-1092	CHEMO	200	mg/m2	1	205	232	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-1092	TARGETED	10	mg/kg	null	119	204	null	BEVACIZUMAB	ADJUVANT	INTRAVENOUS (IV)	
TCGA-12-1092	TARGETED	5	mg	null	460	551	null	RAPAMYCIN	ADJUVANT	ORAL	
TCGA-12-1092	CHEMO	50	mg/m2	3	551	637	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-1092	CHEMO	125	mg/m2	2	368	460	null	CPT 11	ADJUVANT	INTRAVENOUS (IV)	
TCGA-12-1092	TARGETED	150	mg	null	460	551	null	ERLOTINIB	ADJUVANT	ORAL	
TCGA-12-1092	CHEMO	75	mg/m2	1	46	96	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-1092	CHEMO	200	mg/m2	3	119	204	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-1092	CHEMO	50	mg/m2	4	232	367	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-1093	CHEMO	75	mg/m2	1	38	79	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-1093	IMMUNO	1	mL	null	126	317	null	ATTAC	ADJUVANT	ORAL	
TCGA-12-1093	CHEMO	6000	mg	1	339	364	null	Panzem	PROGRESSION	ORAL	
TCGA-12-1093	CHEMO	50	mg/m2	1	339	364	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-1093	CHEMO	1000	mg/m2	5	105	317	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-1094	CHEMO	600	mg/m2	3	141	213	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-1094	CHEMO	125	mg/m2	null	231	269	null	CCNG	PROGRESSION	ORAL	
TCGA-12-1094	CHEMO	100	mg/m2	2	286	336	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-1094	TARGETED	10	mg/m2	null	286	336	null	BEVACIZUMAB	PROGRESSION	ORAL	
TCGA-12-1094	CHEMO	75	mg/m2	1	18	67	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-1094	IMMUNO	1	null	null	104	215	null	ACT PEP3 KLH	ADJUVANT	ORAL	
TCGA-12-1095	CHEMO	75	mg/m2	1	34	82	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-1095	CHEMO	340	mg/m2	4	112	286	null	CPT 11	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-1095	TARGETED	10	mg/m2	null	404	412	null	BEVACIZUMAB	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-1095	TARGETED	10	mg/m2	null	291	370	null	BEVACIZUMAB	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-1095	TARGETED	10	mg/m2	null	95	286	null	BEVACIZUMAB	PROGRESSION	null	
TCGA-12-1095	CHEMO	37.5	mg/m2	1	404	412	null	VP-16	PROGRESSION	ORAL	
TCGA-12-1096	CHEMO	75	mg/m2	1	63	101	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-1096	TARGETED	null	mg/m2	null	202	277	null	BEVACIZUMAB	ADJUVANT	INTRAVENOUS (IV)	
TCGA-12-1096	CHEMO	300	mg/m2	2	130	201	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-1096	CHEMO	250	mg/m2	2	202	277	null	CPT-11	ADJUVANT	INTRAVENOUS (IV)	
TCGA-12-1097	CHEMO	50	mg/m2	1	351	385	null	VP-16	PROGRESSION	ORAL	
TCGA-12-1097	TARGETED	10	mg/kg	null	177	343	null	AMG 102	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-1097	CHEMO	50	mg/m2	1	351	385	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-1097	CHEMO	75	mg/m2	1	49	96	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-1097	CHEMO	200	mg/m2	2	110	166	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-1098	CHEMO	75	mg/m2	1	35	74	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-1099	CHEMO	75	mg/m2	1	61	100	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-1099	TARGETED	10	mg/m2	null	62	103	null	BEVACIZUMAB	PROGRESSION	ORAL	
TCGA-12-1597	null	null	null	null	null	null	null	null	null	null	
TCGA-12-1598	CHEMO	5000	mg	1	33	82	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-1598	CHEMO	4500	mg	3	160	287	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-1599	CHEMO	66750	mg	7	160	391	null	HYDROXYUREA	PROGRESSION	ORAL	
TCGA-12-1599	CHEMO	5300	mg	1	675	727	null	Cytoxan	PROGRESSION	ORAL	
TCGA-12-1599	TARGETED	5520	null	null	438	602	null	null	null	null	
TCGA-12-1599	TARGETED	5520	mg	null	438	602	null	BEVACIZUMAB	PROGRESSION	null	
TCGA-12-1599	CHEMO	5880	mg	1	24	59	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-1599	CHEMO	30000	mg	1	461	492	null	HYDROXYUREA	PROGRESSION	ORAL	
TCGA-12-1599	CHEMO	1600	mg	1	621	671	null	CPT 11	PROGRESSION	INTRAVENOUS (IV)	
TCGA-12-1599	TARGETED	90400	mg	null	160	391	null	IMATINIB	PROGRESSION	null	
TCGA-12-1599	TARGETED	14000	mg	null	406	433	null	ERLOTINIB	PROGRESSION	null	
TCGA-12-1599	TARGETED	280	mg	null	406	433	null	RAPAMYCIN	PROGRESSION	null	
TCGA-12-1599	TARGETED	1840	mg	null	621	671	null	BEVACIZUMAB	PROGRESSION	null	
TCGA-12-1599	TARGETED	1760	mg	null	675	727	null	BEVACIZUMAB	PROGRESSION	null	
TCGA-12-1599	TARGETED	30000	mg	null	461	127	null	IMATINIB	PROGRESSION	null	
TCGA-12-1600	CHEMO	5880	mg	1	43	84	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-1600	CHEMO	12000	mg	4	105	217	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-1602	CHEMO	6000	mg	1	17	56	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-12-1602	CHEMO	8400	mg	2	85	139	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-12-3644	null	null	null	null	null	null	null	null	null	null	
TCGA-12-3646	null	null	null	null	null	null	null	null	null	null	
TCGA-12-3648	null	null	null	null	null	null	null	null	null	null	
TCGA-12-3649	null	null	null	null	null	null	null	null	null	null	
TCGA-12-3650	null	null	null	null	null	null	null	null	null	null	
TCGA-12-3651	null	null	null	null	null	null	null	null	null	null	
TCGA-12-3652	null	null	null	null	null	null	null	null	null	null	
TCGA-12-3653	null	null	null	null	null	null	null	null	null	null	
TCGA-14-0736	CHEMO	8	{Wafer}	null	206	null	null	BCNU	PROGRESSION	OTHER: SPECIFY IN NOTES	
TCGA-14-0736	HORMONAL	null	null	null	0	null	null	DEXAMETHASONE	PROGRESSION	ORAL	
TCGA-14-0736	HORMONAL	null	null	null	127	null	null	DEXAMETHASONE	PROGRESSION	null	
TCGA-14-0736	CHEMO	2000	mg	1	371	376	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-14-0783	HORMONAL	null	null	null	-1	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-0783	CHEMO	108450	mg	null	31	146	null	Carboxy amido triazole	ADJUVANT	ORAL	
TCGA-14-0786	CHEMO	null	null	null	671	null	null	Carboplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-14-0786	CHEMO	3400	mg	1	567	570	null	Streptozocin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-14-0786	CHEMO	null	null	1	140	142	null	CISPLATIN	ADJUVANT	INTRAVENOUS (IV)	
TCGA-14-0786	CHEMO	150	mg	1	526	579	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-14-0786	CHEMO	1200	mg	1	567	570	null	6-Mercaptopurine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-14-0786	HORMONAL	null	null	null	0	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-0786	HORMONAL	null	null	null	127	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-0786	CHEMO	1124	mg	3	182	210	null	CPT 11	ADJUVANT	INTRAVENOUS (IV)	
TCGA-14-0786	CHEMO	null	null	null	671	null	null	Etoposide	ADJUVANT	INTRAVENOUS (IV)	
TCGA-14-0786	CHEMO	null	null	1	140	142	null	BCNU	ADJUVANT	INTRAVENOUS (IV)	
TCGA-14-0786	CHEMO	12600	mg	2	308	357	null	PROCARBAZINE	ADJUVANT	ORAL	
TCGA-14-0786	CHEMO	69	mg	1	567	570	null	BCNU	ADJUVANT	INTRAVENOUS (IV)	
TCGA-14-0786	CHEMO	300	mg	null	574	651	null	THALIDOMIDE	ADJUVANT	ORAL	
TCGA-14-0787	TARGETED	null	null	null	null	null	null	null	ADJUVANT	null	
TCGA-14-0787	HORMONAL	720	mg	null	15	41	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-0789	HORMONAL	1680	mg	null	119	224	null	DEXAMETHASONE	PROGRESSION	ORAL	
TCGA-14-0789	CHEMO	120	mg/day	1	44	75	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-14-0789	CHEMO	8	{Wafer}	1	118	null	null	BCNU Wafer (BCNU)	PROGRESSION	OTHER: SPECIFY IN NOTES	
TCGA-14-0789	HORMONAL	2000	mg	null	0	118	null	DEXAMETHASONE	ADJUVANT	ORAL	
TCGA-14-0790	CHEMO	17700	mg	9	15	409	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-14-0790	HORMONAL	null	mg	null	0	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-0790	CHEMO	8	{Wafer}	null	0	null	null	BCNU BCNU	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-14-0812	CHEMO	8	{Wafer}	null	0	null	null	BCNU Wafers	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-14-0812	HORMONAL	null	null	null	0	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-0813	HORMONAL	16	mg/day	null	0	41	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-0817	HORMONAL	176	mg	null	0	15	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-0865	HORMONAL	null	null	null	0	null	null	DEXAMETHASONE	OTHER: SPECIFY IN NOTES	null	
TCGA-14-0865	HORMONAL	null	null	null	205	null	null	DEXAMETHASONE	PROGRESSION	null	
TCGA-14-0865	CHEMO	9500	mg	4	46	167	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-14-0866	HORMONAL	null	null	null	0	null	null	DEXAMETHASONE	OTHER: SPECIFY IN NOTES	null	
TCGA-14-0866	CHEMO	62415	mg	7	21	325	null	TEMOZOLOMIDE	OTHER: SPECIFY IN NOTES	ORAL	
TCGA-14-0867	HORMONAL	24	mg/day	null	0	15	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-0871	HORMONAL	288	mg	null	-304	280	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-1034	HORMONAL	null	null	null	0	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-1034	CHEMO	8	{Wafer}	null	448	null	null	BCNU	PROGRESSION	OTHER: SPECIFY IN NOTES	
TCGA-14-1034	HORMONAL	null	null	null	274	null	null	DEXAMETHASONE	PROGRESSION	null	
TCGA-14-1037	CHEMO	null	mg	6	25	95	null	Oxaliplatin	ADJUVANT	INTRAVENOUS (IV)	
TCGA-14-1037	HORMONAL	null	null	null	0	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-1037	TARGETED	36.8	mg	null	346	433	null	PS 341	PROGRESSION	INTRAVENOUS (IV)	
TCGA-14-1037	CHEMO	6000	mg	4	439	538	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-14-1037	HORMONAL	null	null	null	326	null	null	DEXAMETHASONE	PROGRESSION	null	
TCGA-14-1396	HORMONAL	null	null	null	null	null	null	DEXAMETHASONE	ADJUVANT	ORAL	
TCGA-14-1401	HORMONAL	null	null	null	null	null	null	DEXAMETHASONE	ADJUVANT	ORAL	
TCGA-14-1402	HORMONAL	null	null	null	304	null	null	Prednisone	ADJUVANT	ORAL	
TCGA-14-1402	TARGETED	14000	mg	null	618	632	null	Sovatenib	PROGRESSION	ORAL	
TCGA-14-1402	CHEMO	63	mg	6	57	66	null	Arsenic Trioxide	ADJUVANT	INTRAVENOUS (IV)	
TCGA-14-1402	HORMONAL	null	null	null	304	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-1402	HORMONAL	null	null	null	333	null	null	DEXAMETHASONE	PROGRESSION	null	
TCGA-14-1402	CHEMO	9500	mg	6	344	528	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-14-1402	CHEMO	4969	mg	6	658	819	null	Carboplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-14-1402	TARGETED	11000	mg	null	658	819	null	BEVACIZUMAB	PROGRESSION	ORAL	
TCGA-14-1451	CHEMO	720	mg	2	501	566	null	BCNU	PROGRESSION	INTRAVENOUS (IV)	
TCGA-14-1451	CHEMO	780	mg	4	411	480	null	CISPLATIN	PROGRESSION	INTRAVENOUS (IV)	
TCGA-14-1451	CHEMO	8	mg	4	411	480	null	VINCRISTINE	PROGRESSION	INTRAVENOUS (IV)	
TCGA-14-1451	TARGETED	9000	mg	null	382	504	null	ERLOTINIB	PROGRESSION	null	
TCGA-14-1451	CHEMO	5880	mg	1	59	101	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-14-1451	HORMONAL	null	null	null	-60	null	null	DEXAMETHASONE	PROGRESSION	null	
TCGA-14-1451	CHEMO	641	mg	2	20	34	null	Oxaliplatin	PROGRESSION	INTRAVENOUS (IV)	
TCGA-14-1451	CHEMO	780	mg	4	411	480	null	Etoposide	PROGRESSION	INTRAVENOUS (IV)	
TCGA-14-1451	CHEMO	8	{Wafer}	null	153	null	null	BCNU	PROGRESSION	OTHER: SPECIFY IN NOTES	
TCGA-14-1451	HORMONAL	null	null	null	19	null	null	DEXAMETHASONE	PROGRESSION	null	
TCGA-14-1452	CHEMO	9,880	mg	3	26	185	null	TEMOZOLOMIDE	OTHER: SPECIFY IN NOTES	ORAL	
TCGA-14-1452	HORMONAL	null	null	null	null	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-1452	CHEMO	8	{Wafer}	null	0	null	null	BCNU	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-14-1452	HORMONAL	null	null	null	172	216	null	DEXAMETHASONE	OTHER: SPECIFY IN NOTES	null	
TCGA-14-1453	HORMONAL	null	null	null	null	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-1454	CHEMO	590,000	mg	18	308	899	null	HYDROXYUREA	PROGRESSION	ORAL	
TCGA-14-1454	HORMONAL	null	null	null	-61	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-1454	HORMONAL	null	null	null	290	null	null	DEXAMETHASONE	PROGRESSION	null	
TCGA-14-1454	CHEMO	236,000	mg	18	308	899	null	IMATINIB	PROGRESSION	ORAL	
TCGA-14-1454	CHEMO	8	{Wafer}	null	0	null	null	BCNU	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-14-1454	CHEMO	15370	mg	7	29	234	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-14-1455	HORMONAL	null	null	null	17	28	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-1455	CHEMO	8	{Wafer}	null	17	null	null	BCNU wafer	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-14-1456	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-14-1458	CHEMO	8400	mg	1	19	60	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-14-1458	CHEMO	6450	mg	3	82	145	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-14-1458	HORMONAL	null	null	null	80	null	null	DEXAMETHASONE	PROGRESSION	null	
TCGA-14-1458	HORMONAL	null	null	null	0	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-1458	TARGETED	10400	mg	null	88	161	null	BEVACIZUMAB	PROGRESSION	INTRAVENOUS (IV)	
TCGA-14-1459	CHEMO	9000	mg	5	22	554	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-14-1459	HORMONAL	null	null	null	null	null	null	DEXAMETHASONE	PROGRESSION	null	
TCGA-14-1459	HORMONAL	null	null	null	null	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-1794	HORMONAL	null	null	null	0	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-1795	HORMONAL	null	null	null	0	59	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-1795	CHEMO	8	{Wafer}	null	0	null	null	BCNU Wafer	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-14-1821	CHEMO	5400	mg	1	39	68	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-14-1821	HORMONAL	null	null	null	0	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-1821	HORMONAL	null	null	null	331	null	null	DEXAMETHASONE	PROGRESSION	null	
TCGA-14-1823	HORMONAL	null	null	null	139	null	null	DEXAMETHASONE	PROGRESSION	null	
TCGA-14-1823	CHEMO	null	null	12	20	449	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-14-1823	HORMONAL	null	null	null	0	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-1823	CHEMO	11150	mg	12	20	449	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-14-1823	CHEMO	8	{Wafer}	null	0	null	null	BCNU Wafers	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-14-1823	TARGETED	6400	mg	null	378	477	null	BEVACIZUMAB	PROGRESSION	null	
TCGA-14-1825	HORMONAL	null	null	null	0	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-1825	HORMONAL	null	null	null	91	null	null	DEXAMETHASONE	PROGRESSION	null	
TCGA-14-1827	CHEMO	null	null	1	42	46	null	CISPLATIN	ADJUVANT	INTRAVENOUS (IV)	
TCGA-14-1827	HORMONAL	null	null	null	0	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-1827	CHEMO	null	null	1	42	46	null	BCNU	ADJUVANT	INTRAVENOUS (IV)	
TCGA-14-1829	HORMONAL	null	null	null	0	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-1829	CHEMO	10040	mg	4	8	null	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-14-2554	HORMONAL	null	mg	null	0	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-2555	CHEMO	12600	mg	4	34	242	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-14-2555	HORMONAL	null	mg	null	0	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-3477	TARGETED	1480	mg	null	56	70	null	BEVACIZUMAB	ADJUVANT	null	
TCGA-14-3477	HORMONAL	null	mg	null	0	null	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-14-3477	CHEMO	4480	mg	1	35	67	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-15-0742	CHEMO	75	mg/m2/day	null	28	59	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-15-0742	TARGETED	200	mg	null	259	300	null	SAHA	ADJUVANT	null	
TCGA-15-1446	CHEMO	null	null	6	61	273	null	Temudar	ADJUVANT	ORAL	
TCGA-15-1447	CHEMO	null	null	2	9	130	null	Temudar	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-15-1447	CHEMO	null	null	2	9	130	null	CPT-11	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-15-1447	CHEMO	null	null	2	9	130	null	BCNU	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-15-1449	CHEMO	null	null	null	32	74	null	Temudar	ADJUVANT	ORAL	
TCGA-16-0846	null	null	null	null	null	null	null	null	null	null	
TCGA-16-0848	null	null	null	null	null	null	null	null	null	null	
TCGA-16-0849	null	null	null	null	null	null	null	null	null	null	
TCGA-16-0850	null	null	null	null	null	null	null	null	null	null	
TCGA-16-0861	null	null	null	null	null	null	null	null	null	null	
TCGA-16-1045	null	null	null	null	null	null	null	null	null	null	
TCGA-16-1047	null	null	null	null	null	null	null	null	null	null	
TCGA-16-1055	null	null	null	null	null	null	null	null	null	null	
TCGA-16-1056	null	null	null	null	null	null	null	null	null	null	
TCGA-16-1060	null	null	null	null	null	null	null	null	null	null	
TCGA-16-1062	null	null	null	null	null	null	null	null	null	null	
TCGA-16-1063	null	null	null	null	null	null	null	null	null	null	
TCGA-16-1460	null	null	null	null	null	null	null	null	null	null	
TCGA-19-0955	CHEMO	360	mg	6	31	274	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-0957	CHEMO	1660	mg	2	565	579	null	BEVACIZUMAB	PROGRESSION	INTRAVENOUS (IV)	
TCGA-19-0957	CHEMO	1660	mg	2	537	551	null	BEVACIZUMAB	PROGRESSION	INTRAVENOUS (IV)	
TCGA-19-0957	CHEMO	1500	mg	1	368	372	null	TEMOZOLOMIDE	RECURRENCE	ORAL	
TCGA-19-0957	CHEMO	1660	mg	2	593	607	null	BEVACIZUMAB	PROGRESSION	INTRAVENOUS (IV)	
TCGA-19-0957	CHEMO	470	mg	2	537	551	null	CPT 11	PROGRESSION	INTRAVENOUS (IV)	
TCGA-19-0957	CHEMO	470	mg	2	593	607	null	CPT 11	PROGRESSION	INTRAVENOUS (IV)	
TCGA-19-0957	CHEMO	5880	mg	6	35	81	null	TEMOZOLOMIDE	OTHER: SPECIFY IN NOTES	ORAL	
TCGA-19-0957	CHEMO	9000	mg	6	121	274	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-0960	CHEMO	300	mg	5	41	null	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-0962	null	null	null	null	null	null	null	null	null	null	
TCGA-19-0963	null	null	null	null	null	null	null	null	null	null	
TCGA-19-0964	CHEMO	140	mg	1	39	82	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-1385	CHEMO	6300	mg	6	16	57	null	TEMOZOLOMIDE	OTHER: SPECIFY IN NOTES	ORAL	
TCGA-19-1385	CHEMO	1600	mg	1	88	92	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-1386	CHEMO	1050	mg	1	230	236	null	ERLOTINIB	ADJUVANT	ORAL	
TCGA-19-1386	CHEMO	5880	mg	4	21	62	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-1386	CHEMO	6000	mg	4	152	244	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-1386	CHEMO	1800	mg	1	216	229	null	ERLOTINIB	ADJUVANT	ORAL	
TCGA-19-1386	CHEMO	1500	mg	1	89	93	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-1387	CHEMO	5600	mg	1	19	58	null	TEMOZOLOMIDE	OTHER: SPECIFY IN NOTES	ORAL	
TCGA-19-1388	CHEMO	9000	mg	6	92	245	null	TEMOZOLOMIDE	OTHER: SPECIFY IN NOTES	ORAL	
TCGA-19-1388	CHEMO	1750	mg	2	363	377	null	BEVACIZUMAB	PROGRESSION	INTRAVENOUS (IV)	
TCGA-19-1388	CHEMO	6020	mg	1	21	63	null	TEMOZOLOMIDE	OTHER: SPECIFY IN NOTES	ORAL	
TCGA-19-1388	CHEMO	6000	mg	1	269	328	null	TEMOZOLOMIDE	PROGRESSION	ORAL	
TCGA-19-1389	CHEMO	2880	mg	1	26	41	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-1389	CHEMO	3600	mg	1	48	67	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-1389	CHEMO	1980	mg	1	10	20	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-1390	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-19-1392	null	null	null	null	null	null	null	null	null	null	
TCGA-19-1786	null	null	null	null	null	null	null	null	null	null	
TCGA-19-1787	CHEMO	null	null	null	null	null	null	null	null	null	
TCGA-19-1788	CHEMO	null	null	1	50	94	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-1789	CHEMO	980	mg	1	26	32	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-1791	null	null	null	null	null	null	null	null	null	null	
TCGA-19-2619	CHEMO	630	mg	10	153	295	null	BEVACIZUMAB	PROGRESSION	INTRAVENOUS (IV)	
TCGA-19-2619	CHEMO	1250	mg	1	113	117	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-2619	CHEMO	3625	mg	1	57	85	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-2620	CHEMO	null	null	1	33	51	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-2621	null	null	null	null	null	null	null	null	null	null	
TCGA-19-2623	CHEMO	1400	mg	1	-255	114	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-2623	CHEMO	4060	mg	1	25	53	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-2623	CHEMO	1200	mg	5	92	null	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-2624	null	null	null	null	null	null	null	null	null	null	
TCGA-19-2625	null	null	null	null	null	null	null	null	null	null	
TCGA-19-2629	CHEMO	null	null	null	null	71	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-19-2629	CHEMO	null	null	null	null	null	null	BEVACIZUMAB	PROGRESSION	INTRAVENOUS (IV)	
TCGA-19-2629	CHEMO	null	null	1	119	null	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-26-1438	CHEMO	5670	mg	1	31	73	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-26-1438	CHEMO	1440	mg	4	104	206	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-26-1438	TARGETED	880	mg	null	221	264	null	Recentin Placebo AXDX2171	PROGRESSION	null	
TCGA-26-1438	CHEMO	210	mg	1	221	221	null	Lomustine	PROGRESSION	ORAL	
TCGA-26-1440	CHEMO	6300	mg	1	30	78	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-26-1440	CHEMO	3140	mg	8	108	null	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-26-1443	CHEMO	5460	mg	1	32	79	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-26-1443	CHEMO	915	mg	3	111	194	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-26-1799	CHEMO	4150	mg	2	101	148	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-27-1830	HORMONAL	4	mg/day	null	-1	70	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-27-1830	CHEMO	420	mg	3	8	86	null	CISPLATIN	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-27-1830	CHEMO	3750	mg	3	8	86	null	TEMOZOLOMIDE	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-27-1831	HORMONAL	307800	mg	null	-8	504	null	Oxcarbazepine	ADJUVANT	ORAL	
TCGA-27-1831	CHEMO	3400	mg	3	6	102	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-27-1831	CHEMO	420	mg	3	4	97	null	CISPLATIN	ADJUVANT	INTRAVENOUS (IV)	
TCGA-27-1831	HORMONAL	4104	mg	null	-8	504	null	DEXAMETHASONE	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-27-1832	CHEMO	3600	mg	3	30	214	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-27-1832	HORMONAL	8	mg/day	null	0	300	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-27-1832	CHEMO	1200	mg	1	214	214	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-27-1833	CHEMO	208	mg	6	184	359	null	Fotemustine	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-27-1833	CHEMO	320	mg	4	184	609	null	CISPLATIN	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-27-1833	CHEMO	3500	mg	4	184	609	null	TEMOZOLOMIDE	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-27-1833	HORMONAL	8	mg/day	null	-6	737	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-27-1833	CHEMO	1300	mg	6	184	725	null	PROCARBAZINE	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-27-1834	CHEMO	1248	mg	6	365	539	null	PROCARBAZINE	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-27-1834	CHEMO	1200	mg	6	365	539	null	Fotemustine	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-27-1834	CHEMO	35000	mg	null	365	662	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-27-1834	CHEMO	6250	mg	5	28	180	null	TEMOZOLOMIDE	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-27-1834	HORMONAL	7302	mg	null	-5	1232	null	DEXAMETHASONE	ADJUVANT	null	
TCGA-27-1834	CHEMO	320	mg	5	28	180	null	CISPLATIN	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-27-1835	CHEMO	160	mg	1	2	3	null	CISPLATIN	ADJUVANT	INTRAVENOUS (IV)	
TCGA-27-1835	HORMONAL	654000	mg	null	-7	648	null	Levetiracetam	ADJUVANT	ORAL	
TCGA-27-1835	HORMONAL	1308	mg	null	-7	648	null	DEXAMETHASONE	ADJUVANT	ORAL	
TCGA-27-1835	CHEMO	8400	mg	5	206	457	null	PC2	RECURRENCE	ORAL	
TCGA-27-1835	CHEMO	12	mL	1	208	208	null	FT	RECURRENCE	INTRAVENOUS (IV)	
TCGA-27-1835	CHEMO	200	mg	1	270	270	null	BCNU	RECURRENCE	INTRAVENOUS (IV)	
TCGA-27-1835	CHEMO	4300	mg	3	4	153	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-27-1836	CHEMO	8400	mg	3	123	184	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-27-1836	CHEMO	8400	mg	3	472	562	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-27-1836	CHEMO	3550	mg	5	245	399	null	PCB	ADJUVANT	ORAL	
TCGA-27-1836	CHEMO	5880	mg	7	48	90	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-27-1836	CHEMO	6720	mg	8	655	760	null	BEVACIZUMAB	ADJUVANT	INTRAVENOUS (IV)	
TCGA-27-1836	HORMONAL	22080	mg	null	-7	914	null	DEXAMETHASONE	ADJUVANT	ORAL	
TCGA-27-1836	CHEMO	896	mg	5	247	399	null	Fotemustine	ADJUVANT	INTRAVENOUS (IV)	
TCGA-27-1836	CHEMO	1440	mg	7	655	760	null	Irunotecan	ADJUVANT	INTRAVENOUS (IV)	
TCGA-27-1836	HORMONAL	828000	mg	null	-7	914	null	Valproic Acid	ADJUVANT	ORAL	
TCGA-27-1837	CHEMO	8750	mg	5	1	152	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-27-1837	CHEMO	800	mg	5	-1	147	null	CDDP	ADJUVANT	INTRAVENOUS (IV)	
TCGA-27-1837	HORMONAL	2592	mg	null	-6	427	null	DEXAMETHASONE	ADJUVANT	ORAL	
TCGA-27-1837	CHEMO	16	mg	4	35	105	null	Doxorubicin	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-27-1838	CHEMO	140	mg	1	1	2	null	CISPLATIN	ADJUVANT	INTRAVENOUS (IV)	
TCGA-27-1838	HORMONAL	216600	mg	null	-11	350	null	Oxcarbazepine	ADJUVANT	ORAL	
TCGA-27-1838	HORMONAL	2214	mg	null	-11	350	null	DEXAMETHASONE	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-27-1838	CHEMO	1500	mg	1	3	7	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-27-2518	CHEMO	580	mg	3	627	700	null	Fotemustine	RECURRENCE	INTRAVENOUS (IV)	
TCGA-27-2518	HORMONAL	5576	mg	null	54	752	null	DEXAMETHASONE	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-27-2518	CHEMO	500	mg	3	19	106	null	CISPLATIN	ADJUVANT	INTRAVENOUS (IV)	
TCGA-27-2518	CHEMO	3600	mg	3	627	700	null	PC2	RECURRENCE	ORAL	
TCGA-27-2518	HORMONAL	1045500	mg	null	54	752	null	Levenracetam	ADJUVANT	ORAL	
TCGA-27-2518	CHEMO	8750	mg	5	21	181	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-27-2519	HORMONAL	null	mg	null	-10	null	null	DEXAMETHASONE	ADJUVANT	ORAL	
TCGA-27-2519	HORMONAL	null	mg	null	-10	null	null	Levetiracetam	ADJUVANT	ORAL	
TCGA-27-2519	CHEMO	6440	mg	1	49	95	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-27-2519	CHEMO	7500	mg	5	133	259	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-27-2519	CHEMO	390	mg	3	302	null	null	Fotemustina	ADJUVANT	INTRAVENOUS (IV)	
TCGA-27-2521	CHEMO	14000	mg	8	91	null	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-27-2521	HORMONAL	null	mg	null	-15	null	null	DEXAMETHASONE	ADJUVANT	ORAL	
TCGA-27-2521	HORMONAL	null	mg	null	-15	null	null	Levetiracetam	ADJUVANT	ORAL	
TCGA-27-2523	CHEMO	15000	mg	10	60	380	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-27-2523	CHEMO	315	mg	2	10	59	null	CISPLATIN	ADJUVANT	INTRAVENOUS (IV)	
TCGA-27-2523	HORMONAL	148500	mg	null	-6	489	null	Phenytoin Sodium	ADJUVANT	ORAL	
TCGA-27-2523	CHEMO	160	mg	1	11	11	null	LOMUSTINE	ADJUVANT	ORAL	
TCGA-27-2523	CHEMO	1500	mg	10	97	396	null	ERLOTINIB	ADJUVANT	ORAL	
TCGA-27-2523	HORMONAL	3960	mg	null	-6	489	null	DEXAMETHASONE	ADJUVANT	ORAL	
TCGA-27-2524	CHEMO	7500	mg	3	58	119	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-27-2524	HORMONAL	948	mg	null	-6	231	null	DEXAMETHASONE	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-27-2524	HORMONAL	142200	mg	null	-6	231	null	Oxcarbazepine	ADJUVANT	ORAL	
TCGA-27-2524	CHEMO	61.6	{Wafer}	null	-6	-6	null	BCNU Wafer	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-27-2526	HORMONAL	744	mg	null	-6	87	null	DEXAMETHASONE	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-27-2527	HORMONAL	444000	mg	null	-7	438	null	Valproic acid	ADJUVANT	ORAL	
TCGA-27-2527	HORMONAL	3552	mg	null	-7	438	null	DEXAMETHASONE	ADJUVANT	ORAL	
TCGA-27-2528	CHEMO	510	mg	4	-2	149	null	CISPLATIN	ADJUVANT	INTRAVENOUS (IV)	
TCGA-27-2528	CHEMO	6000	mg	4	0	160	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-27-2528	HORMONAL	3928	mg	null	-12	479	null	DEXAMETHASONE	ADJUVANT	ORAL	
TCGA-27-2528	HORMONAL	603500	mg	null	-12	479	null	Levetiracetam	ADJUVANT	ORAL	
TCGA-27-2528	CHEMO	1960	mg	1	444	464	null	TEMOZOLOMIDE	RECURRENCE	ORAL	
TCGA-28-1745	CHEMO	7000	mg	5	14	179	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-1745	CHEMO	4500	mg	5	14	179	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-1745	CHEMO	2000	mg	5	14	179	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-1746	null	null	null	null	null	null	null	null	null	null	
TCGA-28-1747	CHEMO	null	mg	1	25	36	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-1749	CHEMO	3800	mg	5	19	158	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-1749	CHEMO	4400	mg	5	19	158	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-1749	CHEMO	7560	mg	5	19	158	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-1750	CHEMO	5040	mg	3	10	115	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-1750	CHEMO	1250	mg	3	10	115	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-1750	CHEMO	1700	mg	3	10	115	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-1751	CHEMO	2600	mg	3	14	207	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-1751	IMMUNO	3	null	null	113	141	null	Dendriticcell Vaccine	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-28-1751	CHEMO	2100	mg	3	14	207	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-1751	CHEMO	6300	mg	3	14	207	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-1752	CHEMO	1800	mg	5	11	272	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-1752	CHEMO	3000	mg	5	11	272	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-1752	CHEMO	1440	mg	5	11	272	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-1752	IMMUNO	3	null	null	104	131	null	Dendriticcell Vaccine	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-28-1752	CHEMO	5880	mg	5	11	272	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-1753	null	null	null	null	null	null	null	null	null	null	
TCGA-28-1755	CHEMO	5040	mg	1	14	56	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-1756	CHEMO	null	mg	null	21	69	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-1757	null	null	null	null	null	null	null	null	null	null	
TCGA-28-1760	CHEMO	150	mg	null	250	null	null	ERLOTINIB	ADJUVANT	INTRAVENOUS (IV)	
TCGA-28-1760	CHEMO	100	mg	null	null	null	null	TEMOZOLOMIDE	ADJUVANT	INTRAVENOUS (IV)	
TCGA-28-1760	CHEMO	1100	mg	null	105	null	null	BEVACIZUMAB	ADJUVANT	INTRAVENOUS (IV)	
TCGA-28-2502	null	null	null	null	null	null	null	null	null	null	
TCGA-28-2506	IMMUNO	null	mL	null	107	135	null	Tumor Vaccine	ADJUVANT	OTHER: SPECIFY IN NOTES	
TCGA-28-2506	TARGETED	null	mg	null	177	null	null	BIBW 2992	PROGRESSION	ORAL	
TCGA-28-2506	CHEMO	null	mg/m2	null	27	72	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-2509	CHEMO	null	mg/m2	null	33	null	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-2509	TARGETED	null	mg/day	null	26	null	null	Cilenaitide	ADJUVANT	INTRAVENOUS (IV)	
TCGA-28-2513	CHEMO	null	mg/day	null	44	null	null	TEMOZOLOMIDE	RECURRENCE	ORAL	
TCGA-28-2513	TARGETED	460	mg	null	44	null	null	BEVACIZUMAB	RECURRENCE	INTRAVENOUS (IV)	
TCGA-28-2513	CHEMO	null	mg/day	null	28	57	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-28-2514	CHEMO	null	mg/m2	null	29	null	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-32-1970	CHEMO	null	null	null	28	67	null	TEMOZOLOMIDE	ADJUVANT	null	
TCGA-32-1976	null	null	null	null	null	null	null	null	null	null	
TCGA-32-1982	CHEMO	null	{Wafer}	null	null	null	null	BCNU Wafer	OTHER: SPECIFY IN NOTES	null	
TCGA-32-1986	CHEMO	null	mg/day	1	null	null	null	TEMOZOLOMIDE	ADJUVANT	ORAL	
TCGA-32-2615	null	null	null	null	null	null	null	null	null	null	
TCGA-32-2616	null	null	null	null	null	null	null	null	null	null	
TCGA-32-2632	null	null	null	null	null	null	null	null	null	null	
TCGA-32-2634	null	null	null	null	null	null	null	null	null	null	
TCGA-32-2638	null	null	null	null	null	null	null	null	null	null	
TCGA-41-2571	null	null	null	null	null	null	null	null	null	null	
TCGA-41-2573	null	null	null	null	null	null	null	null	null	null	
TCGA-41-2575	null	null	null	null	null	null	null	null	null	null	
TCGA-41-3392	null	null	null	null	null	null	null	null	null	null	
